Dapagliflozin

SEP 9, 2026 · PHASE 4 TRIAL

Effect of the Use of Dapagliflozin in Patients With Refractory Heart Failure

ClinicalTrials.gov

This is a clinical trial registry record with no results posted; it describes a planned phase IV crossover study in a small single-centre population with a surrogate renal endpoint, not yet reported.

AUG 13, 2026 · PHASE 2 TRIAL

Sodium-Glucose Cotransporter-2 Inhibitor for Acute Cardiorenal Syndrome: A Feasibility Study

ClinicalTrials.gov

A Phase 2 feasibility study with recruitment completed but no clinical outcome results reported; designed to assess trial feasibility and acceptability rather than efficacy.

JUN 3, 2026 · REGULATORY LABEL UPDATE

FDA supplemental approval: Qtern (Labeling)

U.S. Food and Drug Administration

FDA supplemental labeling approval for Qtern (dapagliflozin/saxagliptin); indicates label modification without new efficacy or safety trial data reported here.

JUN 3, 2026 · REGULATORY LABEL UPDATE

FDA supplemental approval: Farxiga (Labeling)

U.S. Food and Drug Administration

FDA supplemental approval for labeling change to dapagliflozin; does not report clinical trial data or efficacy outcomes.

APR 6, 2026 · REGULATORY APPROVAL

FDA approval: Dapagliflozin

U.S. Food and Drug Administration

FDA approval of a generic dapagliflozin formulation; establishes bioequivalence and manufacturing compliance, not efficacy or clinical superiority.

APR 6, 2026 · REGULATORY APPROVAL

FDA approval: Dapagliflozin

U.S. Food and Drug Administration

FDA approval of a generic dapagliflozin formulation; regulatory action does not establish comparative efficacy or clinical superiority.

APR 6, 2026 · REGULATORY APPROVAL

FDA approval: Dapagliflozin

U.S. Food and Drug Administration

FDA approval of dapagliflozin generic formulations; regulatory action does not evaluate clinical efficacy or comparative benefit.